Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 01/04/2024 at 07:00, 2 years 8 months ago

Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet. The publication highlights the positive results of Sarconeos (BIO101) in reducing the risk of death or respiratory failure in adults hospitalized with severe respiratory symptoms due to COVID-19. Biophytis will also host press conferences to discuss the potential and clinical benefits of Sarconeos (BIO101) in severe forms of COVID-19 and its exploration in the treatment of other respiratory viral infections. For more information, visit www.biophytis.com

Biophytis COVA Phase 2-3 Study Sarconeos (BIO101) Publication Severe COVID-19 Treatment Respiratory Viral Infections Clinical Benefits Of Sarconeos (BIO101)
ARTICLE

published on 12/29/2023 at 07:59, 2 years 8 months ago

Biophytis avance dans son financement avec l'émission de la quatrième tranche d'ORNANE
Biophytis annonce le tirage de la quatrième tranche d'ORNANE auprès du fonds d’investissement Atlas sous le cadre du contrat de financement conclu en 2021

Biophytis Financement ORNANE Atlas Médicament
PRESS RELEASE

published on 12/29/2023 at 07:00, 2 years 8 months ago

Biophytis annonce le tirage de la quatrième tranche d'ORNANE dans le cadre du contrat Atlas 2021
Biophytis annonce le tirage de la quatrième tranche d'ORNANE dans le cadre du contrat Atlas 2021. La société de biotechnologie au stade clinique spécialisée dans le développement de traitements qui visent à ralentir les processus dégénératifs liés au vieillissement va émettre 80 ORNANE pour un montant de 2 millions d’euros, avec une option complémentaire de 80 ORNANE pour un montant de 2 millions d’euros le 15 février 2024

Biophytis ORNANE Atlas 2021 Fonds D'investissement Obligations Remboursables
PRESS RELEASE

published on 12/29/2023 at 07:00, 2 years 8 months ago

Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract
Biophytis, a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases, has announced the drawing of the fourth tranche of its convertible bond agreement with Atlas, a specialized investment fund based in New York. This tranche consists of 80 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with a total value of €4 million. The ORNANE have a 24-month maturity period and do not bear interest. Holders have the option
ARTICLE

published on 12/11/2023 at 07:49, 2 years 9 months ago

Biophytis présente son calendrier de conférences internationales pour le premier trimestre 2024
Biophytis SA confirme sa présence dans des conférences clés du secteur de la santé, visant à renforcer ses relations et à présenter ses avancées

Biophytis Biotechnologie Sarconeos (BIO101) Conférences Traitements Anti-vieillissement
ARTICLE

published on 12/04/2023 at 08:00, 2 years 9 months ago

Biophytis et l'Université de Liège s'associent pour combattre l'insuffisance respiratoire virale
Biophytis annonce un partenariat avec l'Université de Liège pour étudier Sarconeos (BIO101) dans le traitement de pathologies respiratoires

Biophytis Université De Liège Insuffisance Respiratoire Recherche Préclinique Médicament Sarconeos
PRESS RELEASE

published on 11/27/2023 at 07:00, 2 years 9 months ago

Biophytis nomme Yann Meunier et Bernard Lévy à son comité scientifique
PRESS RELEASE

published on 11/20/2023 at 07:00, 2 years 10 months ago

Biophytis annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription pour un montant d’environ 1,96 M€
PRESS RELEASE

published on 11/17/2023 at 23:00, 2 years 10 months ago

Biophytis reçoit une notification du Nasdaq
PRESS RELEASE

published on 11/06/2023 at 07:00, 2 years 10 months ago

Biophytis to attend BIO-Europe in Munich

Published on 09/23/2026 at 22:00, 3 hours 36 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 7 hours 11 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 9 hours 54 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 11 hours 5 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 11 hours 6 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

View all ACCESSWIRE

Published on 09/23/2026 at 23:00, 2 hours 36 minutes ago

Correction d’un communiqué du 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNONCE LE SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION AINSI QU’UN REMBOURSEMENT PARTIEL D’OBLIGATIONS REMBOURSABLES EN ACTIONS
Published on 09/23/2026 at 23:00, 2 hours 36 minutes ago

Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 5 hours 44 minutes ago

LIGHTON: LightOn renouvelle son financement obligataire auprès des mêmes partenaires financiers pour un montant nominal maximum de 4 millions d’euros, et étend ainsi son horizon de trésorerie
Published on 09/23/2026 at 19:51, 5 hours 44 minutes ago

LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 19:30, 6 hours 6 minutes ago

EUROPLASMA: Valdunes Industries et Saarstahl Ascoval s’associent pour développer une nouvelle génération de « roues vertes »

View all EQS

Published on 09/23/2026 at 19:46, 5 hours 49 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 5 hours 49 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 6 hours 21 minutes ago

Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 19:14, 6 hours 21 minutes ago

Performance robuste des Investissements, poursuite du déploiement de la stratégie
Published on 09/23/2026 at 18:00, 7 hours 36 minutes ago

CIS : H1 2026 results.

View all LES ECHOS COMFI WIRE

News